Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - Celsion Corporation

Drug Profile

Doxorubicin liposomal - Celsion Corporation

Alternative Names: Liposome encapsulated doxorubicin; LTLD; LTSDEL; Lyso-thermosensitive liposomal doxorubicin; ThermoDox

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celsion Corporation
  • Developer Brigham and Womens Hospital; Celsion Corporation; Focused Ultrasound Foundation; Harvard Medical School; University of Oxford
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Breast cancer; Colorectal cancer; Liver metastases
  • Preclinical Bladder cancer
  • No development reported Brain cancer; Glioblastoma; Pancreatic cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 04 Nov 2019 Efficacy data from the phase III OPTIMA trial in Liver cancer released by Celsion Corporation
  • 23 Oct 2019 Celsion completes the phase III OPTIMA trial in Liver cancer in USA, Canada, China, Germany, Hong Kong, Italy, South Korea, Malaysia, Philippines, Singapore, Spain, Taiwan, Thailand and Vietnam (NCT02112656)
  • 27 Aug 2019 Updated efficacy data from the phase III HEAT trial in Liver cancer released by Celsion Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top